CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges

被引:1
|
作者
Jonaitis, Erin M. [1 ,2 ,3 ]
Jeffers, Beckie [1 ,2 ,3 ]
VandenLangenberg, Monica [2 ,3 ]
Ma, Yue [2 ]
Van Hulle, Carol [2 ]
Langhough, Rebecca [2 ,3 ]
Du, Lianlian [2 ,4 ]
Chin, Nathaniel A. [3 ]
Przybelski, Robert J. [3 ]
Hogan, Kirk J. [5 ]
Christian, Bradley T. [2 ,6 ,7 ]
Betthauser, Tobey J. [2 ,3 ]
Okonkwo, Ozioma C. [2 ,3 ]
Bendlin, Barbara B. [2 ,3 ]
Asthana, Sanjay [2 ,8 ]
Carlsson, Cynthia M. [1 ,2 ,8 ]
Johnson, Sterling C. [1 ,2 ]
机构
[1] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, 600 Highland Ave CSC K6-440 MC4670, Madison, WI 53792 USA
[2] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr & Gerontol, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI 53792 USA
[6] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53792 USA
[8] Wm S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
D O I
10.1093/clinchem/hvad221
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background The sensitivity of amyloid to pre-analytic factors complicates cerebrospinal fluid (CSF) diagnostics for Alzheimer disease. We report reliability and validity evidence for automated immunoassays from frozen and fresh CSF samples in an ongoing, single-site research program.Methods CSF samples were obtained from 2 Wisconsin cohorts (1256 measurements; 727 participants). Levels of amyloid beta 1-42 (A beta 42), phosphorylated tau 181 (pTau181), and total tau (tTau) were obtained using an Elecsys cobas e 601 platform. Repeatability and fixed effects of storage tube type, extraction method, and freezing were assessed via mixed models. Concordance with amyloid positron emission tomography (PET) was investigated with 238 participants having a temporally proximal PET scan.Results Repeatability was high with intraclass correlation (ICC) >= 0.9, but tube type strongly affected measurements. Discriminative accuracy for PET amyloid positivity was strong across tube types (area under the curve [AUC]: A beta 42, 0.87; pTau181A beta 42 , 0.96), although optimal thresholds differed.Conclusions Under real-world conditions, the Elecsys platform had high repeatability. However, strong effects of pre-analytic factors suggest caution in drawing longitudinal inferences.
引用
收藏
页码:538 / 550
页数:13
相关论文
共 50 条
  • [41] CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
    Cousins, Katheryn Alexandra Quilico
    Arezoumandan, Sanaz
    Shellikeri, Sanjana
    Ohm, Daniel
    Shaw, Leslie M.
    Grossman, Murray
    Wolk, David
    McMillan, Corey T.
    Chen-Plotkin, Alice
    Lee, Edward
    Trojanowski, John Q.
    Zetterberg, Henrik
    Blennow, Kaj
    Irwin, David John
    NEUROLOGY, 2022, 99 (20) : E2303 - E2312
  • [42] CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
    Hanna Rosenmann
    Journal of Molecular Neuroscience, 2012, 47 : 1 - 14
  • [43] CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
    Delvenne, Aurore
    Gobom, Johan
    Schindler, Suzanne E.
    ten Kate, Mara
    Reus, Lianne M.
    Dobricic, Valerija
    Tijms, Betty M.
    Benzinger, Tammie L. S.
    Cruchaga, Carlos
    Teunissen, Charlotte E.
    Ramakers, Inez
    Martinez-Lage, Pablo
    Tainta, Mikel
    Vandenberghe, Rik
    Schaeverbeke, Jolien
    Engelborghs, Sebastiaan
    De Roeck, Ellen
    Popp, Julius
    Peyratout, Gwendoline
    Tsolaki, Magda
    Freund-Levi, Yvonne
    Lovestone, Simon
    Streffer, Johannes
    Barkhof, Frederik
    Bertram, Lars
    Blennow, Kaj
    Zetterberg, Henrik
    Visser, Pieter Jelle
    Vos, Stephanie J. B.
    ALZHEIMERS & DEMENTIA, 2024, 20 (09) : 6205 - 6220
  • [44] Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease
    Grimmer, Timo
    Goldhardt, Oliver
    Yakushev, Igor
    Ortner, Marion
    Sorg, Christian
    Diehl-Schmid, Janine
    Foerstl, Hans
    Kurz, Alexander
    Perneczky, Robert
    Miners, Scott
    NEURODEGENERATIVE DISEASES, 2019, 19 (01) : 43 - 50
  • [45] Current Biomarkers for Alzheimer's Disease: From CSF to Blood
    Zou, Kun
    Abdullah, Mohammad
    Michikawa, Makoto
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (03): : 1 - 15
  • [46] CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
    Janelidze, Shorena
    Mattsson, Niklas
    Stomrud, Erik
    Lindberg, Olof
    Palmqvist, Sebastian
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    NEUROLOGY, 2018, 91 (09) : E867 - E877
  • [47] CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
    Rosenmann, Hanna
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 47 (01) : 1 - 14
  • [48] Author Correction: Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
    Fardin Nabizadeh
    Homa Seyedmirzaei
    Shaghayegh Karami
    Scientific Reports, 14 (1)
  • [49] Alzheimer's disease risk biomarkers: progress and challenges
    Adkins-Jackson, Paris B.
    Belsky, Daniel W.
    LANCET HEALTHY LONGEVITY, 2022, 3 (09): : E575 - E576
  • [50] LONGITUDINAL CHANGES IN PROTEOMIC BIOMARKERS IN ALZHEIMER'S DISEASE AND CARDIOVASCULAR DISEASE
    Theeke, Laurie
    Liu, Ying
    Wang, Silas
    Navia, R. Osvaldo
    Xiao, Danqing
    Xu, Chun
    Wang, Kesheng
    INNOVATION IN AGING, 2023, 7 : 1158 - 1158